Search

Vinay O Bhaskar

from West New York, NJ
Age ~45
Get Report
Connected to:
Akhilesh Bhaskar, 40Amrit M Bhaskar, 87Anitha N Bhaskaran, 50Anusha Bhaskar, 35Balasundaram N Bhaskaran, 46Bhinu Bhaskaran, 44Deepak Bhaskaran, 40Deepthi S Bhaskar, 43Hemant Bhaskar, 45Irene L Bhaskaran, 50

Vinay Bhaskar Phones & Addresses

  • West New York, NJ
  • Hanover, NH
  • Ithaca, NY
  • Alpharetta, GA

Publications

Wikipedia References

Vinay Bhaskar Photo 2

Vinay Bhaskar

About:
Born:

Warangal , Andhra Pradesh

Skills & Activities:
Activity:

Telugu politician

Us Patents

Activatable Interleukin-2 Polypeptides And Methods Of Use Thereof

View page
US Patent:
20210403524, Dec 30, 2021
Filed:
May 14, 2021
Appl. No.:
17/320779
Inventors:
- Cambridge MA, US
Daniel HICKLIN - Montclair NJ, US
Vinay BHASKAR - San Francisco CA, US
Luke EVNIN - San Francisco CA, US
Patrick BAEUERLE - Gauting, DE
Jose Andres SALMERON GARCIA - Westminster MA, US
Heather BRODKIN - West Newton MA, US
International Classification:
C07K 14/55
A61P 35/00
C07K 16/28
Abstract:
The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable Interleukin 12 Polypeptides And Methods Of Use Thereof

View page
US Patent:
20200283489, Sep 10, 2020
Filed:
May 21, 2020
Appl. No.:
16/880624
Inventors:
- Cambridge MA, US
Daniel Hicklin - Montclair NJ, US
Vinay Bhaskar - San Francisco CA, US
Luke Evnin - San Francisco CA, US
Patrick Baeuerle - Gauting, DE
Jose Andres Salmeron Garcia - Westminster MA, US
Heather Brodkin - West Newton MA, US
International Classification:
C07K 14/54
C07K 16/28
Abstract:
The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable Interleukin-2 Polypeptides And Methods Of Use Thereof

View page
US Patent:
20200283490, Sep 10, 2020
Filed:
May 21, 2020
Appl. No.:
16/880606
Inventors:
- Cambridge MA, US
Daniel Hicklin - Montclair NJ, US
Vinay Bhaskar - San Francisco CA, US
Luke Evnin - San Francisco CA, US
Patrick Baeuerle - Gauting, DE
Jose Andres Salmeron Garcia - Westminster MA, US
Heather Brodkin - West Newton MA, US
International Classification:
C07K 14/55
A61P 35/00
C07K 16/28
Abstract:
The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable Interleukin-2 Polypeptides And Methods Of Use Thereof

View page
US Patent:
20200040052, Feb 6, 2020
Filed:
Jun 11, 2019
Appl. No.:
16/438156
Inventors:
- Cambridge MA, US
Daniel HICKLIN - Montclair NJ, US
Vinay BHASKAR - San Francisco CA, US
Luke EVNIN - San Francisco CA, US
Patrick BAEUERLE - Gauting, DE
Jose Andres SALMERON GARCIA - Westminster MA, US
Heather BRODKIN - West Newton MA, US
International Classification:
C07K 14/55
C07K 16/28
A61P 35/00
Abstract:
The disclosure features fusion proteins that are conditionally active variants of IL-2. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Activatable Interleukin 12 Polypeptides And Methods Of Use Thereof

View page
US Patent:
20190367576, Dec 5, 2019
Filed:
Jun 11, 2019
Appl. No.:
16/438166
Inventors:
- Cambridge MA, US
Daniel HICKLIN - Montclair NJ, US
Vinay BHASKAR - San Francisco CA, US
Luke EVNIN - San Francisco CA, US
Patrick BAEUERLE - Gauting, DE
Jose Andres SALMERON GARCIA - Westminster MA, US
Heather BRODKIN - West Newton MA, US
International Classification:
C07K 14/54
C07K 16/28
Abstract:
The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.
Control profile
Vinay O Bhaskar from West New York, NJ, age ~45 Get Report